This funding supports phased research to identify patient phenotypes and validate molecular mechanisms underlying CNS complications in people with HIV. It aims to advance therapeutic target discovery through innovative in-vitro and in-vivo experimental models, addressing the multifactorial nature of HIV-associated CNS dysfunction. Clinical trials are not allowed under this opportunity.
Eligible applicants include U.S. state, county, city, and special district governments; public and private higher education institutions; Native American tribal governments and organizations; nonprofits; for-profit organizations excluding small businesses; and small businesses. Foreign organizations
